Nuvectis Pharma, Inc.
NASDAQ:NVCTBiotechnology
+$0.39 today
- Market cap
- $697.75M
- Beta
- -0.07
- P/E (TTM)
- -11.2
- EPS (TTM)
- -$1.16
Volume 0.19M
Average 0.08M
NVCT Gross Margin
Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.
Gross Margin history
Percent of revenue · from the income statement
No Gross Margin data reported for this period type.
Gross Margin vs competitors
How NVCT compares with its peers on the latest reported figures
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 98.0% | -0.0 pp | — | |
| LTM Jun 2026 | 93.9% | +66.4 pp | — | |
| LTM Mar 2026 | 83.7% | -16.3 pp | -17.1 pp | |
| LTM Mar 2026 | 69.9% | +7.9 pp | -24.0 pp | |
| LTM Mar 2026 | 54.1% | +476.2 pp | -10.5 pp | |
| LTM Mar 2026 | -105.7% | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| Peer median (excluding NVCT) | 76.8% | +7.9 pp | -17.1 pp | |
Competitors are the stored peer set for NVCT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 9.55M | 13.23M | 15.38M | 12.92M | 18.15M |
| Selling, General & Admin | 3.35M | 6.01M | 7.52M | 6.93M | 9.42M |
| Operating Expenses | 12.89M | 19.23M | 22.9M | 19.85M | 27.57M |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | 0 |
| EBITDA | (12.89M) | (19.09M) | (22.26M) | (19M) | (26.44M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (12.89M) | (19.23M) | (22.9M) | (19.85M) | (27.57M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 4K | 149K | 637K | 847K | 1.13M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 4K | 149K | 637K | 847K | 1.13M |
| Income Before Tax | (12.89M) | (19.09M) | (22.26M) | (19M) | (26.44M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (12.89M) | (19.09M) | (22.26M) | (19M) | (26.44M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.09) | (1.51) | (1.43) | (1.11) | (1.32) |
| EPS (Diluted) | (1.09) | (1.51) | (1.43) | (1.11) | (1.32) |
| Weighted Avg Shares | 12.72M | 12.66M | 15.56M | 17.11M | 21.81M |
| Weighted Avg Shares (Diluted) | 12.72M | 12.66M | 15.56M | 17.11M | 21.81M |
Nuvectis Pharma, Inc.
NASDAQ:NVCT
Intrinsic Alpha fair value
Locked
Current Price
$20.29
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.